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OBJECTIVE—In humans, multiple genes in the interleukin
(IL)-2/IL-2 receptor (IL-2R) pathway are associated with type 1
diabetes. However, no link between IL-2 responsiveness and
CD4CD25FOXP3 regulatory T-cells (Tregs) has been dem-
onstrated in type 1 diabetic subjects despite the role of these
IL-2– dependent cells in controlling autoimmunity. Here, we
address whether altered IL-2 responsiveness impacts persis-
tence of FOXP3 expression in Tregs of type 1 diabetic
subjects.
RESEARCH DESIGN AND METHODS—Persistence of Tregs
was assessed by culturing sorted CD4CD25hi natural Tregs
with IL-2 and measuring FOXP3 expression over time by flow
cytometry for control and type 1 diabetic populations. The
effects of IL-2 on FOXP3 induction were assessed 48 h after
activation of CD4CD25 T-cells with anti-CD3 antibody.
Cytokine receptor expression and signaling upon exposure to
IL-2, IL-7, and IL-15 were determined by flow cytometry and
Western blot analysis.
RESULTS—Maintenance of FOXP3 expression in CD4CD25
Tregs of type 1 diabetic subjects was diminished in the presence
of IL-2, but not IL-7. Impaired responsiveness was not linked to
altered expression of the IL-2R complex. Instead, IL-2R signaling
was reduced in Tregs and total CD4 T-cells of type 1 diabetic
subjects. In some individuals, decreased signal transducer and
activator of transcription 5 phosphorylation correlated with
significantly higher expression of protein tyrosine phosphatase
N2, a negative regulator of IL-2R signaling.
CONCLUSIONS—Aberrant IL-2R signaling in CD4 T-cells of
type 1 diabetic subjects contributes to decreased persistence
of FOXP3 expression that may impact establishment of toler-
ance. These findings suggest novel targets for treatment of
type 1 diabetes within the IL-2R pathway and suggest that an
altered IL-2R signaling signature may be a biomarker for type
1 diabetes. Diabetes 59:407–415, 2010
There are two major classes of FOXP3 regula-tory T-cells (Tregs): natural Tregs (nTregs),which develop in the thymus and control periph-eral immune responses to self-antigens, and in-
duced Tregs (iTregs), which can be generated from
peripheral blood CD4CD25 T-cells (1,2). Although the
ontogeny of human peripheral blood FOXP3 T-cells is
still debated, it is clear that interleukin (IL)-2 strongly
influences the biology of both nTregs and iTregs (3–5). IL-2
regulates FOXP3 expression in a signal transducer and
activator of transcription 5 (STAT5)–dependent manner
(6), and both IL-2 and STAT5 are required for the periph-
eral generation of iTregs (5,7) and maintenance of nTregs
(8,9). The dependence of Tregs on IL-2 has been clearly
demonstrated in knockout mice where deficiency of IL-2,
IL-2 receptor- (IL-2R), or IL-2R leads to early death
due to severe autoimmunity caused by a lack of FOXP3
T-cells (10–12). In rare human cases, deficiency in IL-2R
results in autoimmunity, lymphadenopathy, and persistent
viral infection (13,14), whereas deficiency of STAT5b
results in decreased frequency and function of Tregs (15).
Together, these data emphasize the essential role of IL-2/
IL-2R signaling—and specifically, STAT5 activation—in
peripheral tolerance mediated by Tregs.
IL-2 is a T-cell growth factor and key cytokine involved
in immune regulation that is produced in a transient
manner primarily by activated effector T-cells (4). Binding
of IL-2 to the high-affinity IL-2R results in a wide range of
biological responses including survival, differentiation,
and proliferation of multiple cell types including T-cells.
The IL-2R consists of a heterotrimer composed of an
-chain (CD25), a -chain (CD122) shared with the IL-15R,
and the common -chain (CD132) shared with the IL-7R,
IL-9R, IL-15R, and IL-21R. Engagement of the IL-2R results
in a cascade of signaling events initiated by phosphoryla-
tion of the tyrosine kinases Janus kinase 1 (JAK1) and
JAK3 followed by phosphorylation of tyrosine residues on
the IL-2R -chain that results in phosphorylation of STAT5
and Shc. These proximal activation events lead to down-
stream signaling cascades, resulting in activation of IL-2–
dependent genes such as FOXP3 (16). Negative regulators
of the IL-2 signaling cascades, including protein tyrosine
phosphatases, control the intensity and kinetics of these
responses (17,18).
In NOD mice, there is a decrease in the frequency and
function of Tregs at the site of inflammation (19), as well
as alterations in the IL-2/IL-2R pathway (20). Recent
studies have linked defects in Tregs in NOD mice to
reduced availability of IL-2. These include reports of the
association of the Idd3 susceptibility locus to decreased
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IL-2 production, resulting in impaired Treg function and
proliferation at sites of inflammation (21–23). Further-
more, this Treg defect in NOD mice can be rescued by
treatment with exogenous IL-2 (22). In humans, the IL-2
gene itself and genes that participate in IL-2R signaling,
including CD25 and PTPN2, have been implicated in the
pathogenesis of type 1 diabetes (20,24–28). However, to
date, no studies have demonstrated a functional link
between IL-2/IL-2R signaling and Treg deficits in humans
diagnosed with type 1 diabetes.
Maintenance of FOXP3 expression is essential for the
function of Tregs in vivo and has been shown in both mice
and humans to be dependent on common -chain cyto-
kines, with IL-2 playing a dominant role (7,9). Here, we
demonstrate that maintenance of FOXP3 expression in
both nTregs and iTregs is diminished in CD4CD25
T-cells of type 1 diabetic subjects when cultured in the
presence of IL-2. This was associated with diminished
IL-2R signaling in response to IL-2, as measured by de-
creased phosphorylation of STAT5, but not with altered
IL-2R expression. Decreased STAT5 phosphorylation cor-
related with an increase in protein tyrosine phosphatase
N2 (PTPN2) expression in CD4 T-cells of type 1 diabetic
subjects.
RESEARCH DESIGN AND METHODS
Human subjects. Samples for this study were obtained from subjects
diagnosed with type 1 diabetes and control subjects with no personal or family
history of autoimmunity who are participants in the Juvenile Diabetes
Research Foundation International (JDRF) Center for Translational Research
protocol approved by institutional review boards at both Benaroya Research
Institute and Seattle Children’s Hospital. Subjects provided written informed
consent prior to participation in the study. A total of 66 type 1 diabetic
subjects (mean age 32  13 years, range 18–58) and 125 control subjects
(mean age 35  12, range 18–67) were used in these studies. The number of
samples used for each assay is indicated in figure legends. All experiments
were performed in a blinded manner without prior knowledge of disease state.
Antibodies and reagents. BD Pharmingen (San Jose, CA) antibodies used
include fluorescein isothiocyanate– conjugated CD25; AlexaFlour488
STAT5(pY694); phycoerythrin-conjugated CD25, CD122, CD132, and
STAT5(pY694); peridinin-chlorophyll-protein complex– conjugated CD4;
allophycocyanin-conjugated CD4, CD45RO, and CD25; and purified anti-CD3
(UCH11) and anti-CD28 (CD28.2). Intracellular AlexaFlour647-conjugated
anti-FOXP3 (clone 259D) and matching isotype control were purchased from
Biolegend (San Diego, CA). For immunoblots, goat polyclonal anti-PTPN2
antibody was purchased from R&D Systems (Minneapolis, MN); polyclonal
rabbit anti-JAK1, polyclonal rabbit anti-JAK3, and monoclonal rabbit anti-
STAT5 were purchased from Cell Signaling Technologies. Rabbit polyclonal
anti–transcription factor (TF) IIB antibody was used as a loading control
(Santa Cruz Biotechnology, Santa Cruz, CA) with horseradish peroxidase–
coupled rabbit anti-goat IgG (Novus Biologicals, Littleton, CO) secondary
antibody. IL-2 was purchased from Chiron (Emeryville, CA). IL-7 and IL-15
were purchased from BD Pharmingen. A small molecule inhibitor of PTPN2
(compound 8) was prepared as described (29).
Flow cytometric analysis for phosphorylated STAT5. BD Biosciences
Phosphoflow staining was performed as per the manufacturer’s instructions.
In brief, cells were activated with different concentrations of IL-2, IL-7, or
IL-15 for 10 and/or 20 min, fixed with BD Biosciences Phosflow Buffer I, and
permeabilized using BD Phosflow Buffer III prior to staining with anti-
pSTAT5(Y694), CD4, and CD25. For some experiments, cells were costained
with CD122 and CD45RO. Initial experiments were performed using freshly
isolated peripheral blood mononuclear cells (PBMCs). Similar results were
obtained with thawed PBMCs. All pSTAT5 data shown here are from
previously frozen PBMCs. Data were acquired using a FACSCalibur (BD
Biosciences, San Diego, CA) and analyzed using FlowJo (TreeStar, Ashland,
OR) or Winlist software (Verity Software House, Topsham, ME). Because
CD4CD25 T-cells are known to be sensitive to the freeze/thaw process and
fix/perm staining protocols, samples where less than 1% of CD25 T-cells were
detected were not analyzed for pSTAT5. pSTAT5(Y694) mean fluorescence
intensity (MFI) data were normalized between experiments by determining
the MFI fold increase (geometric MFI of the positive population/geometric
MFI of the negative control) as described previously (30).
Isolation and activation of cells. Human peripheral blood was obtained
from donors, and PBMCs were prepared by centrifugation over Ficoll-
Hypaque gradients. For some experiments, previously processed and frozen
PBMCs were used. CD4 T-cells and accessory cells were purified as
described previously (31). For some freshly isolated samples, CD25hi (top
2–5%) were further isolated from CD4 T-cells by sorting using a FACSVan-
tage (BD Biosciences).
For persistence assays, sorted CD4CD25hi T-cells (nTregs) were seeded in
a 96-well plate at a concentration of 1.5  106/ml in a total volume of 200 l.
Cells were cultured with media alone or cytokine without stimulation through
the T-cell receptor. Cells were stained for CD25, CD4, and FOXP3 expression
on different days after the sort. Surface expression of CD25, CD122, and
CD132 was quantified using Quantum R-PE MESF beads (Bangs Laboratories)
to calculate molecules of equivalent soluble fluorochrome (MESF).
For induction assays, CD4CD25 T-cells were activated with 5 g/ml
soluble anti-CD3 bound to irradiated (5,000 rad) accessory cells at a concen-
tration of 1.5  106/ml as described previously (31). No cytokine, IL-2 (200
IU/ml), or IL-7 (10 ng/ml) was added at the initiation of culture. FOXP3
content in iTregs was determined by flow cytometry.
Western blot analysis. Expression of IL-2 pathway proteins was analyzed in
peripheral CD4 T-cells isolated from fresh PBMCs. Whole-cell lysates were
separated by denaturing SDS-PAGE (20 g protein per lane) using NuPage
10% or 4–12% Bi-Tris gels as indicated by the manufacturer (Invitrogen,
Carlsbad, CA) and transferred to Immobilon P membranes (Millipore, Bil-
lerica, MA). Immunoblots were probed with primary antibodies followed by
horseradish peroxidase–coupled secondary antibody. Staining was detected
by chemiluminescence (Perkin-Elmer Life Sciences). Protein expression was
quantified by densitometry of films using ImageQuant Software Version 5.1
(GE Healthcare, Piscataway, NJ).
Statistics. For analysis of experiments comparing a single variable, statistical
significance was determined using two-tailed independent or paired Student t
tests as noted in the figure legends. For analysis of multiple variables, an
ANCOVA was performed. All analyses were performed using GraphPad Prism
V4.03 and all values with P 	 0.05 were considered significantly different.
RESULTS
Maintenance of FOXP3 expression in CD4CD25
T-cells is diminished in type 1 diabetic subjects. We
compared persistence of FOXP3 expression in nTregs of
type 1 diabetic subjects and control subjects to determine
whether the maintenance of FOXP3 expression is im-
paired in type 1 diabetic subjects. Persistence of FOXP3
was determined by culturing nTregs (FACS-sorted
CD4CD25 T-cells) in the presence of media or IL-2 and
then measuring FOXP3 expression over time by flow
cytometry, as diagramed in Figure 1A. Consistent with
prior studies (7), FOXP3 expression in CD4CD25 T-cells
of control subjects was maintained in the presence of IL-2,
but not media alone. In contrast, FOXP3 persistence was
significantly decreased in nTregs of type 1 diabetic sub-
jects cultured in the presence of IL-2 as illustrated for one
subject in Figure 1B and a cohort of 17 control (mean
6.42  8.2 SD, 
 FOXP3 [day 4  day 0]) and 13 type 1
diabetic (mean 17.98  15.3 SD, 
 FOXP3 [day 4  day
0]) subjects in Figure 1C. This effect was specific to IL-2 as
there was no difference between the study populations
when nTregs were cultured in the presence of media or
IL-7.
The decrease in FOXP3 persistence in type 1 diabetic
subjects did not appear to be due to differences in survival
of nTregs as there was no difference in viable cell counts,
absolute number of FOXP3 cells, or CD95 expression
between control and type 1 diabetic subjects when cells
were cultured in the presence of IL-2 (supplementary Data
1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0694/DC1). More-
over, FOXP3 expression in nTregs of control subjects, but
not type 1 diabetic subjects, cultured in media could be
rescued by addition of IL-2 midculture (supplementary
Data 2). It is possible that the composition of nTregs in
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control and type 1 diabetic subjects differs, thereby
contributing to altered persistence of FOXP3 in the
presence of IL-2. However, we found no difference in the
frequency of resting CD45RAFOXP3 or activated
CD45RAFOXP3hi cells, two recently described subsets of
nTregs (32,33), in the cohort of control and type 1 diabetic
subjects assessed in Figure 1 (supplementary Data 3). In
fact, demethylation of the FOXP3 gene, an additional
marker of Tregs (34,35), was similar in nTregs of control
and type 1 diabetic subjects (supplementary Data 4).
Moreover, persistence of FOXP3 was comparable between
control and type 1 diabetic subjects in the presence of IL-7.
Together, these data indicate that the decrease in FOXP3
persistence was not strongly influenced by differences in
cell differentiation among the CD4CD25hi sorted
populations.
nTregs of type 1 diabetic subjects display impaired
IL-2R signaling. A decreased responsiveness to IL-2 in
nTregs may be due to altered expression of components of
the IL-2R or altered function of the IL-2R signaling cas-
cade. Flow cytometric analysis was performed to examine
the level of CD25, CD122, and CD132 expression on
CD4CD25 T-cells. In these studies, expression of IL-2R
components was comparable between control and type 1
diabetic subjects (Fig. 2A). Additionally, no differences in
the level of CD25 expression in the study populations were
observed after 4 days of culture (data not shown).
To address function of the IL-2R signaling pathway, we
measured phosphorylation of STAT5 (pSTAT5) in the
CD4CD25 population by flow cytometry after exposure
to IL-2 as shown in Figure 2B for a representative control
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FIG. 1. Maintenance of FOXP3 expression in CD4CD25 nTregs of
type 1 diabetic subjects is impaired in the presence of IL-2. As
diagramed in (A), fresh CD4CD25 T-cells were sorted from PBMCs
isolated from control and type 1 diabetic subjects, placed in culture
with media alone or 200 IU/ml IL-2, and FOXP3 and CD25 expression
was assessed over time by flow cytometry. B: One control and one type
1 diabetic sample are shown. C: CD4CD25 T-cells from multiple
control (n  17) and type 1 diabetic (n  13) subjects were assayed as
in A in the presence of media alone, 200 IU/ml IL-2, or 10 ng/ml IL-7.
Bars show means and symbols represent individual subjects. Analysis
was performed by gating on live CD4CD25 T-cells. Statistical signif-
icance was determined using an independent Student t test. Cohorts of
control and type 1 diabetic subjects had mean ages of 38 (range 18–61)
and 34 (range 21–46) years, respectively.
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signaling. A: Level of expression of CD25, CD122, and CD132 in the
CD4CD25 population of control (n  17) and type 1 diabetic (n 
11) subjects from Fig. 1C was determined using Quantum R-PE MESF
beads. B: Thawed PBMCs from a representative control and type 1
diabetic subject were stimulated with 100 IU/ml IL-2 for 20 min prior to
fixation and staining with CD4, CD25, and pSTAT5(Y694). Dashed
lines are treatment with media alone and solid lines are treatment with
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were stimulated as in B. Bars show means and symbols represent
individual subjects. Analysis of pSTAT5 was performed by gating on
live CD4CD25 T-cells. Statistical significance was determined using
an independent Student t test.
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and type 1 diabetic sample. When analyzing a cohort of
subjects, we found that the majority (85.83  12.4% SD) of
CD4CD25 T-cells isolated from control subjects re-
sponded to IL-2 stimulation as measured by pSTAT5. In
comparison, significantly fewer (72.44  15.2% SD)
CD4CD25 T-cells of type 1 diabetic subjects responded
to IL-2 (P  0.0307) (Fig. 2C). Similar differences in
pSTAT5 between Tregs of control and type 1 diabetic
subjects were observed at different time points and with
different doses of IL-2 (supplementary Data 5). Moreover,
the level of total STAT5 protein expression did not signif-
icantly contribute to the frequency of pSTAT5 as the level
of total STAT5 protein did not differ between control and
type 1 diabetic subjects and the relative expression of
STAT5 did not correlate with pSTAT5 frequencies for
either population (supplementary Data 6). Together, these
data suggest that decreased IL-2 responsiveness in nTregs
of type 1 diabetes is linked to defects in IL-2R signaling.
To determine whether the effects of IL-2 on FOXP3
expression altered other IL-2–dependent Treg popula-
tions, we compared induction of FOXP3 expression in
control and type 1 diabetic subjects by stimulating
CD4CD25 T-cells with soluble anti-CD3 and irradiated
antigen-presenting cells in the presence of media alone,
IL-2, or IL-7 and measured FOXP3 expression after 48 h.
Expression of FOXP3 upon activation in the presence of
IL-2 was significantly lower in type 1 diabetic than control
CD4 T-cells, whereas no difference was seen between the
two populations when CD4 T-cells were activated in the
presence of media alone or IL-7 (Fig. 3A). To rule out
the possibility that the decrease in FOXP3 expression in
CD4 T-cells of type 1 diabetic subjects stimulated in the
presence of IL-2 was due to differences in total activation
between control and type 1 diabetic populations, we
analyzed CD69 expression levels. We found that CD69
expression levels were comparable between the control
and type 1 diabetic study populations, whereas FOXP3
expression in type 1 diabetic subjects was diminished
compared with control subjects in the presence of IL-2
when analyzed with respect to CD69 (Fig. 3B and C).
Comparable results were obtained using CD25 as an
activation marker (supplementary Data 7). Thus, modula-
tion of FOXP3 expression by IL-2 is diminished in both
nTregs and iTregs of type 1 diabetic subjects.
Diminished IL-2 responsiveness in CD4 T-cells of
type 1 diabetic subjects is a stable phenotype associ-
ated with impaired IL-2R signaling. To better define the
mechanism of decreased IL-2 responsiveness in T-cells of
type 1 diabetic subjects, we measured STAT5 activation in
total CD4 T-cells, as diagrammed in Figure 4A after
exposure to IL-2. Experimental conditions included expo-
sure to media alone, IL-2, IL-15, or IL-7, all of which share
the common -chain receptor component. IL-2 and IL-15
also share the IL-2R -chain. Consistent with other reports
(30), the majority of CD25 T-cells phosphorylate STAT5
in response to IL-2, whereas a subset of CD4CD25
T-cells also respond to IL-2. When analyzing a cohort of
control and type 1 diabetic subjects, we found a significant
decrease in the frequency of total CD4 T-cells that
phosphorylated STAT5 in response to higher (100 IU/ml)
and lower (25 IU/ml) doses of IL-2 (Fig. 4B). A similar
decrease in responsiveness of CD4 T-cells from type 1
diabetic subjects was observed upon IL-15 exposure, but
not upon exposure to IL-7, suggesting a defect in signaling
associated with the IL-2R -chain, which is shared be-
tween IL-2 and IL-15, but not IL-7 (Fig. 4C). Similarly, the
levels of pSTAT5 in response to IL-2 and IL-15 as measured
by MFI were significantly decreased in type 1 diabetic
compared with control subjects, whereas responses to
IL-7 were similar in these study populations (Fig. 4D). The
decrease in pSTAT5 observed here was not due to obvious
differences in the composition of the T-cell compartments
of control and type 1 diabetic subjects as no difference was
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FIG. 3. FOXP3 expression in iTregs of type 1 diabetic subjects is
impaired in the presence of IL-2 but not IL-7. A: CD4CD25 T-cells
were isolated from previously frozen control (n  15) and type 1
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presence of 100 IU/ml IL-2 to determine the association between CD69
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observed between the frequency of control and type 1
diabetic CD45RO and CD122 CD4 T-cells in this study
(data not shown). Thus, CD4 T-cells of type 1 diabetic
subjects display diminished responsiveness to IL-2 that
may be associated with signaling through the -chain of
the IL-2R.
To measure whether impaired IL-2R signaling is a prop-
erty of CD4 T-cells of type 1 diabetic subjects, we
compared pSTAT5 responses of CD4 T-cells from the
same individual stimulated with either IL-2 or IL-15. Over-
all, responsiveness to IL-2 correlated with responsiveness
to IL-15 (Fig. 5A). This was a stable phenotype, as CD4
T-cells isolated from the same individual at different times
responded similarly to IL-2 stimulation (Fig. 5B). Thus,
CD4 T-cells of individual type 1 diabetic subjects consis-
tently display impaired responsiveness to both IL-2 and
IL-15, suggesting an intrinsic property of type 1 diabetic
CD4 T-cells linked to the -chain of the IL-2R.
Increased expression of PTPN2 in type 1 diabetic
subjects correlates with decreased STAT5 activation.
Decreased pSTAT5 in type 1 diabetic subjects may be due
to alterations in the level of expression of molecules that
participate in the IL-2R signaling pathway. To address this
question, we measured protein expression levels of
STAT5, JAK1, JAK3, and the negative regulator, PTPN2, in
CD4 T-cells of control and type 1 diabetic subjects (Fig.
6 and supplementary Data 6 and 8). We then compared
these expression levels to pSTAT5 responses after expo-
sure to IL-2. No differences were found in STAT5, JAK3, or
JAK1 protein expression comparing control and type 1
diabetic subjects. By contrast, PTPN2 expression was
uniform in control subjects but was increased overall in
type 1 diabetic subjects, with some type 1 diabetic sub-
jects showing a fourfold greater level of expression com-
pared with control subjects (Fig. 6C). This increased
expression of PTPN2 correlated with decreased pSTAT5
after IL-2 exposure (Fig. 6D), consistent with a down-
modulatory role of PTPN2 (18). In type 1 diabetic subjects
with high PTPN2 expression, decreased IL-2 response
could be rescued by pretreatment with a PTPN2 inhibitor
(29) (Fig. 6E and F). In fact, where PTPN2, pSTAT5, and
FOXP3 persistence was measured in the same individual,
we found that a type 1 diabetic subject with elevated
PTPN2 expression also showed reduced pSTAT5 (4.84% of
CD4, 100 IU/ml for 10 min) and diminished persistence of
FOXP3 expression (18.92, 
 FOXP3 [day 4  day 0]).
Together, these data suggest that increased expression of
PTPN2 in CD4 T-cells of some type 1 diabetic subjects
may contribute to reduced levels of pSTAT5 in response to
IL-2.
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CD4 T-cells and comparing response to media alone versus cytokine stimulation. A: Staining for one representative sample is shown. B: The
frequency of CD4 T-cells that were pSTAT5(Y694) in response to IL-2 was determined for control (n  59) and type 1 diabetic (n  33)
subjects. Bars represent means and symbols represent individual subjects. C: Control (n 12) and type 1 diabetic (n 13) subjects were assayed
for pSTAT5(Y694) in response to stimulation for 10 min with 200 pg/ml IL-15 or 40 pg/ml IL-7. Bars represent means  SEM. D: MFI fold increase
of pSTAT5(Y694) in STAT5 CD4 T-cells of thawed PBMCs from control (n  12) and type 1 diabetic (n  14) subjects was determined by
comparing pSTAT5(Y694) MFI after stimulation with IL-2, IL-7, and IL-15, or media alone. Bars show means and symbols represent individual
subjects. All P values were determined using an independent Student t test.
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DISCUSSION
Although the precise mechanisms by which IL-2 influences
CD4CD25FOXP3 Treg control of type 1 diabetes are
currently being dissected in mouse models, many basic
questions remain to be answered regarding FOXP3 Tregs
in humans diagnosed with type 1 diabetes. Previous stud-
ies in type 1 diabetic subjects have focused on the number
and function of Tregs (36–41). Given the established role
of IL-2 and IL-2R signaling in Treg maintenance (42) and
the association of genes within the IL-2/IL-2R pathway
with type 1 diabetes (20,24–28), we investigated whether
IL-2–dependent persistence of Tregs was impaired in type
1 diabetic subjects. We found that maintenance of FOXP3
expression in the presence of IL-2 was decreased in both
nTregs and iTregs of type 1 diabetic subjects. This corre-
lated with alterations in the IL-2R -chain signaling path-
way, as opposed to expression levels of components of the
IL-2R, suggesting that this diminished responsiveness to
IL-2 may contribute to loss of tolerance in type 1 diabetic
subjects.
The decrease in FOXP3 persistence observed here in
nTregs and iTregs of type 1 diabetic subjects suggests that
resistance to IL-2 may result in a decrease in the persis-
tence of Tregs in vivo. However, the frequency of FOXP3
T-cells in the peripheral blood does not differ between
control and type 1 diabetic subjects (36). IL-2 is produced
primarily by effector T-cells upon activation at the site of
inflammation and, in this manner, IL-2 production controls
local Treg frequency and function (22,43,44), whereas IL-7
is produced primarily by stromal cells and can also sup-
port homeostasis of lymphocyte populations including
FOXP3 Tregs (45). Thus, persistence of Tregs in type 1
diabetic subjects may be diminished at the sites of inflam-
mation due to decreased responsiveness to IL-2 produced
during inflammation, although peripheral homeostasis of
the FOXP3 Treg population may not be affected. This is
consistent with the observation that the frequency of
Tregs in NOD mice is impaired in the -islets and pancre-
atic lymph nodes but not in peripheral sites (22). Alterna-
tively, currently, measures of Treg frequency detected ex
vivo may not be sensitive enough to measure alterations in
the biology of Tregs, however, when challenged in vitro,
deficiencies in the maintenance of Tregs of type 1 diabetic
subjects may become more obvious. Here we show a
deficit in Treg persistence in type 1 diabetic subjects,
however, immune regulation by Tregs is also diminished in
type 1 diabetic subjects through an additional mechanism.
Effector T-cells of type 1 diabetic subjects are more
resistant to regulation than effector T-cells of control
subjects (40). Taken together, we suggest a model in
which IL-2–dependent FOXP3 persistence may be de-
creased at the site of inflammation due to impaired respon-
siveness to IL-2, and effector T-cells may be more resistant
to regulation by these less stable Tregs, together resulting
in unregulated organ-specific inflammation.
Reduced IL-2 responsiveness is likely a result of im-
paired activation of STAT5 through the IL-2R -chain as
CD4 T-cells of type 1 diabetic subjects displayed dimin-
ished pSTAT5 in response to both IL-2 and IL-15, cytokines
with receptors containing the IL-2R -chain, but not IL-7.
Several mouse models shed light on the role of IL-2R
-chain on FOXP3 Treg biology (reviewed in [4,20]) and,
when taken into consideration with data shown here,
reveal possible mechanisms of immune dysregulation in
type 1 diabetic subjects. Mice lacking both IL-2 and IL-15
have reduced numbers of Tregs that can be rescued by
forced expression of constitutively active STAT5 (3,8).
When the active form of STAT5 was constitutively ex-
pressed (46,47) or specific tyrosine residues within the
cytoplasmic domain of the IL-2R -chain were mutated
(48), a clear link was shown between IL-2 responsiveness
and Treg development and homeostasis. Here, we find that
FOXP3 expression in the presence of IL-2 is reduced
compared with control subjects but can be rescued in the
presence of IL-7. This is consistent with a requirement for
STAT5 activation through the IL-2R -chain. Together,
these data suggest that impaired persistence of FOXP3 in
Tregs of type 1 diabetes may be due to defects in IL-2R
-chain signaling and offer novel options for targeted
therapy.
Decreased pSTAT5 in response to IL-2 was observed not
only in nTregs but also in total CD4 T-cells, suggesting an
intrinsic property of CD4 T-cells of type 1 diabetic
subjects. In fact, a similar decrease in pSTAT5 upon
exposure to IL-2 was observed with CD8 T-cells (data not
shown). Whether this intrinsic property of CD4 T-cells of
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FIG. 5. Diminished IL-2 responsiveness is a stable phenotype and
intrinsic property of CD4 T-cells of type 1 diabetes. A: Thawed PBMCs
from control (n  18) and type 1 diabetic (n  20) subjects were
stimulated with 100 IU/ml IL-2 or 200 pg/ml IL-15 for 10 min prior to
fixation and staining for CD4, CD25, and pSTAT5(Y694). Linear re-
gression was performed to determine the relationship between
pSTAT5 responses in the same cells after stimulation with either IL-2
or IL-15. Trend lines represent linear regression of control (R2 
0.3713, P 0.0073) and type 1 diabetes (R2 0.2003, P 0.0478) data.
B: Cells isolated from the same individual but at different dates were
assayed as described (in A) for response to IL-2. Sample collection
dates varied from 5 months to 6 years. The number of months between
sample collection did not correlate with SD or coefficient of variation
for the control subjects, type 1 diabetic subjects, or all samples
combined as analyzed by linear regression.
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type 1 diabetes is due to genetic and/or environmental
factors is not clear. Multiple genes in the IL-2/IL-2R
pathway are associated with type 1 diabetes (20,24–28),
but none to date has been found to associate with im-
paired Treg biology in type 1 diabetes. More studies with
other autoimmune diseases, type 2 diabetic subjects, and
first-degree relatives are required to better determine
whether this phenotype is specific to type 1 diabetes. More
broadly, this defect may have additional implications for
other biological processes that require IL-2.
Increased expression of PTPN2 in CD4 T-cells of some
type 1 diabetic subjects suggests a molecular mechanism
for the reduced responsiveness to IL-2 in type 1 diabetic
subjects. Consistent with the down-modulatory role of
PTPN2 in signal transduction (17), others have shown a
role for PTPN2 in decreasing STAT1 phosphorylation in
response to IFN stimulation of human -islet cells (49).
Here, we show for the first time that in some type 1
diabetic subjects PTPN2 protein is significantly increased
in CD4 T-cells, a cell subset of the immune system known
to express high amounts of PTPN2 (50). We further
demonstrate a mechanistic link between increased expres-
sion of PTPN2 in type 1 diabetic subjects and decreased
pSTAT5 by rescuing IL-2 responsiveness with a PTPN2-
specific inhibitor. However, some type 1 diabetic subjects
have diminished pSTAT5 in response to IL-2 but the level
of PTPN2 expression is comparable with control subjects.
This suggests that in some type 1 diabetic subjects in-
creased expression of PTPN2 may contribute to altered
IL-2 responsiveness, whereas in others, different molecu-
lar mechanisms may be involved, both resulting in a
decreased pSTAT5 phenotype. Two independent variants
within introns of the PTPN2 gene are associated with type
1 diabetes (27) and may impact PTPN2 expression. This is
the focus of current research in our laboratory. Interest-
ingly, when we analyze control and type 1 diabetic sub-
jects that do not carry risk-alleles of PTPN2, we still find a
significant difference in PTPN2 expression and pSTAT5
(S.A.L., K.C., and J.B., unpublished data).
Cytokine signaling signatures are associated with auto-
immune diseases. Here, we demonstrate that two pheno-
types of CD4 T-cells of type 1 diabetic subjects involve
molecules in the IL-2R signaling pathway. Whether altered
PTPN2 and pSTAT5 phenotypes indicate a comprehensive
defect in the IL-2R signaling pathway of type 1 diabetes is
not yet known. However, in conjunction with further
studies, these data may suggest that CD4 T-cells of type
1 diabetes are marked by altered IL-2R signaling. Gaining
a better understanding of the mechanisms leading to these
phenotypes may guide development of diagnostic assays
and targeted therapies.
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FIG. 6. Altered expression of molecules in the IL-2R signaling cascade in CD4 T-cells of type 1 diabetic subjects. CD4 T-cells were isolated from
fresh PBMCs of control and type 1 diabetic subjects, and whole-cell protein lysates were analyzed by Western blot. Immunoblots were probed with
JAK1-, JAK3-, and PTPN2-specific antibodies and an anti-TFIIB antibody as a loading control. Protein expression was determined by
densitometry, normalizing each sample to TFIIB and expressing total protein levels relative to a Jurkat control present on each blot. Total JAK1
(A) and JAK3 (B) protein expression was compared between control (n  20) and type 1 diabetic (n  18 and 20 for JAK1 and JAK3,
respectively) subjects. C: PTPN2 protein expression was compared between control (n  21) and type 1 diabetic (n  18) subjects. Significance
was determined using an independent Student t test. D: Thawed PBMCs from these same samples were assayed for pSTAT5 upon exposure with
100 IU/ml IL-2 for 10 min as in Fig. 4. Using linear regression, protein expression was compared with pSTAT5 for control (n  13) and type 1
diabetic (n  15) subjects. Correlation between PTPN2 protein expression in the total population (control and type 1 diabetic subjects
combined) and pSTAT5 is noted in the graph. Solid trend line (R2  0.02, P  0.6) and squares denote control subjects, and dashed trend line
(R2  0.234, P  0.067) and open circles denote type 1 diabetic subjects. E: Thawed PBMCs from the type 1 diabetic subject with the highest
PTPN2 expression or (F) type 1 diabetic subject with PTPN2 expression above the mean 0.8 (n  6) were incubated with a PTPN2 inhibitor
(compound 8 in [29]) for 30 min prior to stimulation with IL-2 for 10 min as in Fig. 4.
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